Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
JNJ 
Johnson & Johnson (JNJ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/10/2025: JNJ (3-star) is a STRONG-BUY. BUY since 84 days. Simulated Profits (22.63%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
24 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $187.49
1 Year Target Price $187.49
| 7 | Strong Buy |
| 4 | Buy |
| 13 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 12.83% | Avg. Invested days 48 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/10/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 459.32B USD | Price to earnings Ratio 20.4 | 1Y Target Price 187.49 |
Price to earnings Ratio 20.4 | 1Y Target Price 187.49 | ||
Volume (30-day avg) 24 | Beta 0.39 | 52 Weeks Range 137.37 - 192.10 | Updated Date 10/12/2025 |
52 Weeks Range 137.37 - 192.10 | Updated Date 10/12/2025 | ||
Dividends yield (FY) 2.63% | Basic EPS (TTM) 9.35 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-14 | When Before Market | Estimate 2.76 | Actual - |
Profitability
Profit Margin 25% | Operating Margin (TTM) 28.91% |
Management Effectiveness
Return on Assets (TTM) 7.61% | Return on Equity (TTM) 30.21% |
Valuation
Trailing PE 20.4 | Forward PE 16.42 | Enterprise Value 479783863414 | Price to Sales(TTM) 5.07 |
Enterprise Value 479783863414 | Price to Sales(TTM) 5.07 | ||
Enterprise Value to Revenue 5.29 | Enterprise Value to EBITDA 13.46 | Shares Outstanding 2408338872 | Shares Floating 2404533697 |
Shares Outstanding 2408338872 | Shares Floating 2404533697 | ||
Percent Insiders 0.06 | Percent Institutions 74.42 |
Upturn AI SWOT
Johnson & Johnson
Company Overview
History and Background
Johnson & Johnson was founded in 1886 by Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson. Initially focused on sterile surgical dressings, it grew through innovation and acquisitions to become a diversified healthcare giant.
Core Business Areas
- Innovative Medicine: Focuses on discovering, developing, and delivering innovative medicines in therapeutic areas such as immunology, oncology, neuroscience, cardiovascular, and infectious diseases. Also provides prescription products.
- MedTech: Offers a broad range of medical devices, surgical products, orthopedics, vision care and solutions used in a wide range of procedures.
- Consumer Health: J&J spun off Kenvue, its consumer health products division. Previously, this segment focused on over-the-counter medicines, skin health, and essential health products. Products like Band-Aids, Tylenol, and Neutrogena were part of this division.
Leadership and Structure
Joaquin Duato is the current CEO. Johnson & Johnson operates with a decentralized structure, allowing each segment to function with a degree of autonomy.
Top Products and Market Share
Key Offerings
- Stelara: A biologic therapy used to treat autoimmune diseases like psoriasis, Crohn's disease, and ulcerative colitis. Competitors: Humira (ABBV), Remicade (JNJ) (biosimilars), Skyrizi (ABBV) and Entyvio (TAK). Stelara's 2022 revenue was $9.7B.
- Darzalex: A monoclonal antibody used in the treatment of multiple myeloma. Competitors: Amgen (AMGN)'s Kyprolis, Bristol Myers Squibb (BMY)'s Empliciti and Pomalyst. Darzalex's 2022 revenue was $7.97B.
- Invega Sustenna/Xeplion: A long-acting injectable antipsychotic medication for schizophrenia treatment. Competitors: Risperdal Consta (JNJ), Abilify Maintena (OTSU), and others. Generates roughly $4 billion in annual revenue.
Market Dynamics
Industry Overview
The healthcare industry is characterized by increasing regulatory scrutiny, rapid technological advancements, and growing demand for innovative therapies and medical devices due to an aging population.
Positioning
Johnson & Johnson is a leading player in the healthcare industry, with a strong reputation for innovation, quality, and a diversified portfolio of products and services. Its competitive advantage lies in its R&D capabilities, global reach, and brand recognition.
Total Addressable Market (TAM)
The total addressable market for pharmaceuticals and medical devices is estimated to be in the trillions of dollars globally. J&J is well-positioned within this TAM due to its diverse portfolio.
Upturn SWOT Analysis
Strengths
- Diversified business segments (Pharmaceuticals, Medical Devices)
- Strong R&D capabilities and innovation pipeline
- Global presence and distribution network
- Strong brand recognition and reputation
- Robust financial performance
Weaknesses
- Exposure to litigation and product liability claims
- Dependence on key products and patent expirations
- Integration challenges from acquisitions
- Consumer health business separation could cause initial market uncertainty
- High debt after multiple acquisitions
Opportunities
- Expanding into emerging markets
- Developing new therapies for unmet medical needs
- Acquiring complementary businesses and technologies
- Leveraging digital health and data analytics
- Focus on value-based healthcare
Threats
- Increasing competition from generic drugs and biosimilars
- Pricing pressures from governments and payers
- Regulatory changes and healthcare reforms
- Economic downturns and healthcare spending cuts
- Geopolitical risks
Competitors and Market Share
Key Competitors
- PFE
- MRK
- ABBV
- BMY
- TMO
Competitive Landscape
Johnson & Johnson faces intense competition across its business segments. Its ability to innovate and adapt to changing market dynamics will be crucial for maintaining its competitive edge.
Major Acquisitions
Abiomed
- Year: 2022
- Acquisition Price (USD millions): 16600
- Strategic Rationale: Expanded J&J's MedTech portfolio with innovative heart recovery technology.
Shockwave Medical
- Year: 2024
- Acquisition Price (USD millions): 13100
- Strategic Rationale: Augment J&J's cardiovascular intervention platform.
Growth Trajectory and Initiatives
Historical Growth: Johnson & Johnson has historically grown through organic growth, acquisitions, and new product development.
Future Projections: Analysts project moderate revenue growth driven by pharmaceuticals and medical devices.
Recent Initiatives: Recent strategic initiatives include acquisitions of medical device companies, focusing on innovative pharmaceutical research, and the spin-off of Kenvue.
Summary
Johnson & Johnson remains a strong player in the healthcare industry, bolstered by its pharmaceutical and medical device segments. While it has a diversified portfolio and robust financial performance, litigation risks and competition are challenges. Recent strategic initiatives, like acquisitions and the consumer health spin-off, aim to drive future growth. Johnson and Johnson needs to be aware of competition from generic drugs, biosimilars and keep up with product liability claims.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Analyst Reports (e.g., from Reuters, Bloomberg, Yahoo Finance)
- Company Website (Investor Relations)
- Industry Reports (e.g., from IBISWorld, McKinsey)
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market data and estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Johnson & Johnson
Exchange NYSE | Headquaters New Brunswick, NJ, United States | ||
IPO Launch date 1944-09-24 | CEO & Chairman Mr. Joaquin Duato | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 138100 | Website https://www.jnj.com |
Full time employees 138100 | Website https://www.jnj.com | ||
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.